HDAC inhibitors for the treatment of cutaneous T-cell lymphomas

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma

(2011) V Cheriyath et al.   BRITISH JOURNAL OF CANCER

Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor β (TGFβ) Receptor II Leading to Cancer Cell Death

(2011) Sanjib Chowdhury et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

(2011) Thomas Robert et al.   NATURE

Cancer cells’ epigenetic composition and predisposition to histone deacetylase inhibitor sensitization

(2011) Narasimharao Nalabothula et al.   Epigenomics

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

(2010) J. J. Campbell et al.   BLOOD

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

(2010) U Lassen et al.   BRITISH JOURNAL OF CANCER

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells

(2010) CE Tiffon et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

(2010) N. L. Steele et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma

(2010) M. B. Wozniak et al.   HAEMATOLOGICA

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance

(2010) Wenlin Shao et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

(2010) Jasmine Zain et al.   INVESTIGATIONAL NEW DRUGS

Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and Sézary Syndrome

(2010) Madeleine Duvic et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Infectious agents in cutaneous T-cell lymphoma

(2010) Ezra D. Mirvish et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

(2010) Elise A. Olsen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients

(2010) Evangelos Terpos   LEUKEMIA RESEARCH

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

Mitochondria and cell death: outer membrane permeabilization and beyond

(2010) Stephen W. G. Tait et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair

(2010) J.- H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

(2009) L. Ellis et al.   BLOOD

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

(2009) Susan E. Bates et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

(2009) Susan Fotheringham et al.   CANCER CELL

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

(2009) Ulrike Heider et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma

(2009) Kelley A. Vidulich et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome

(2009) Jennifer M. Gardner et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

(2009) Q-L Zhang et al.   LEUKEMIA

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

(2009) C. Choudhary et al.   SCIENCE

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism

(2008) J. Chen et al.   BLOOD

Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome

(2008) R. Talpur et al.   BRITISH JOURNAL OF DERMATOLOGY

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate

(2008) Matthias Steinhoff et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Valproic Acid and All-Trans Retinoic Acid: Meta-Analysis of a Palliative Treatment Regimen in AML and MDS Patients

(2008) Frauke Bellos et al.   Oncology Research and Treatment